Katherine R. Tuttle

Aug 1, 2024 | jacc.org | Richard E. Pratley |Katherine R. Tuttle |Peter Rossing |Søren Bo Rasmussen

Introduction Heart failure (HF) affects an estimated 64 million people worldwide.1 The increasing global prevalence of HF is due to an aging population, as well as increasing rates of hypertension, coronary artery disease, obesity, type 2 diabetes (T2D), and chronic kidney disease (CKD).2-8 When T2D and CKD coexist, the risk for HF and mortality is increased beyond that of either condition alone.9 Therefore, developing better strategies for HF prevention and treatment in high-risk patients...

Apr 15, 2024 | ahajournals.org | Brendon L Neuen |Katherine R. Tuttle |Muthiah Vaduganathan

REFERENCES1. Rossing P, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, . KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.Kidney Int. 2022; 102:S1–S127. doi: 10.1016/j.kint.2022.06.008CrossrefMedlineGoogle Scholar2. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, . Management of hyperglycemia in type 2 diabetes, 2022.

Apr 3, 2024 | nature.com | Paola Fioretto |Frederik Persson |Sylvia E. Rosas |Peter Rossing |Jennifer Schaub |Katherine R. Tuttle | +1 more

AbstractDiabetic kidney disease (DKD), defined as co-existing diabetes and chronic kidney disease in the absence of other clear causes of kidney injury, occurs in approximately 20–40% of patients with diabetes mellitus. As the global prevalence of diabetes has increased, DKD has become highly prevalent and a leading cause of kidney failure, accelerated cardiovascular disease, premature mortality and global health care expenditure.

Jan 2, 2024 | nature.com | Louise Maple-Brown |Katherine R. Tuttle

The theme of World Kidney Day 2024 is “kidney health for all — advancing equitable access to care and optimal medication practice”. To mark this event, Nature Reviews Nephrology invited five researchers from different geographical regions worldwide to discuss the impact of new and emerging therapies for diabetic kidney disease on patient care as well as the barriers that must be overcome to ensure equitable access to these therapies.

Mar 1, 2023 | jci.org | Katherine R. Tuttle |Jennifer Schaub |Matthias Kretzler |Petter Bjornstad

AbstractThe sodium-glucose cotransporter-2 (SGLT2) is expressed on the luminal side of proximal tubule epithelial cells in the kidney. While pharmacological inhibition of SGLT2 provides kidney protection in diabetic kidney disease (DKD), the molecular mechanisms remain unclear. In this issue of the JCI, Schaub et al. report on the changes in single-cell transcriptional profiles of young participants with type 2 diabetes who received SGLT2 inhibitors.